Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Flavivirus Infections Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Homologous Re-infection With Dengue 1 or Dengue 3

NCT05967455
View directory record Official record
Conditions
Dengue
Interventions
Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults

NCT00537147
View directory record Official record
Conditions
West Nile Fever
Interventions
WN/DEN4delta30 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147
View directory record Official record
Conditions
Dengue
Interventions
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

NCT02317900
View directory record Official record
Conditions
Dengue
Interventions
TV005, Placebo, rDEN2∆30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dengue 3 Human Infection Model (DENV-3)

NCT04298138
View directory record Official record
Conditions
Dengue
Interventions
Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

Diagnosis and Characterization of Dengue Fever in Children

NCT00946218
View directory record Official record
Conditions
Dengue Fever
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 11 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GLS-5700 in Dengue Virus-Naïve Adults

NCT02809443
View directory record Official record
Conditions
Healthy
Interventions
GLS-5700
Biological
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

NCT00473135
View directory record Official record
Conditions
Dengue
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Human Immune Responses to Yellow Fever Vaccination

NCT00694655
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA)
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

NCT03425149
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection
Interventions
VLA1601, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 22, 2026, 2:17 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT07706686
View directory record Official record
Conditions
Healthy Volunteers, Dengue, Human Challenge Trial
Interventions
rDEN2delta30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

NCT01488890
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
7
States / cities
Alabaster, Alabama • Sacramento, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

NCT02450838
View directory record Official record
Conditions
Dengue
Interventions
V180, Alhydrogel™, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age

NCT02879266
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

NCT01943825
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever
Interventions
CYD Dengue Vaccine, Japanese Encephalitis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Examine the Effects of Oral Fenretinide

NCT06528457
View directory record Official record
Conditions
Dengue
Interventions
ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo
Drug · Other
Lead sponsor
Island Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

NCT03641339
View directory record Official record
Conditions
Zika, Dengue, Malaria, Chikungunya, Leishmaniasis
Interventions
One vector feeding, Four vector feeding
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

NCT03110770
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions
VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 35 Years
Enrollment
2,428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Miami, Florida • Edinburg, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Jul 22, 2026, 2:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults

NCT00616356
View directory record Official record
Conditions
Yellow Fever
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jul 22, 2026, 2:17 AM EDT